Substitute for form 1449A/PTO		Complete If Known		
INFORMATION DISCLOSURE	Application Number	09/845,716		
STATEMENT BY APPLICANT	Filing Date	May 2, 2001		
(use as mathr streets as necessary)	First Named Inventor	Soren NIELSEN		
A	Group Art Unit	1647		
OCT 0 1 2001 (5)	Examiner Name	Debern		
Sheet 1 of 2	Attorney Docket Number	NIELSEN3A		
MADEMARK				

U.S. PATENT DOCUMENTS						
Examiner Cite	Cite No.¹	U.S. Patent Docume	nt	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines,
A A	NO.	Number known)	Kind Code ² (if		Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
AN)	AA	50,28592		LIPTON	07-02-1991	
	AB	5731408		HADLEY, et al.	03-24-1998	
	AC	5830994		D'HINTERLAND, et al.	11-03-1998	
	AD	5835382		WILSON, et al.	11-10-1998	
-44 <u>/</u> 1)	AE	5986047		WRIGHTON, et al.	11-16-1999	
-						

FOREIGN PATENT DOCUMENTS								
Examiner Cite No.	Cite			ment	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines,	
	140.	Office ³	Number	Kind Code ⁵ (if known)		Cited Document MM-DD-YYYY		T⁵
HV)	AF	wo	8704623		UNIVERSITY PATENTS INC.	08-13-1987		
	AG	wo	8800833		BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	02-11-1988		
	AH	wo	9641815		DUSSOURD D'HINTERLAND	12-27-1996		
	AJ	wo	9921571		TREGA BIOSCIENCES, INC.	05-06-1999		
	A.J	wo	9957148		WA PHARM AB	11-11-1999		
	AK	wo	0032772		ELI LILLY AND CO.	06-08-2000		
MQV)	AL	EP	0972522		L'OREAL-DPI	01-19-2000		

Examiner Signature Date Considered 1005

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ¹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449APTO		Complete if Known		
INFORMATION DISCLOSURE	Application Number	09/845,716		
STATEMENT BY APPLICANT	Filing Date	May 2, 2001·		
(use as many sheets as necessary)	First Named Inventor	Soren NIELSEN		
OCT 0 1 2001)	Group Art Unit	647		
	Examiner Name	Deberry		
Sheet 2 of 2	Attorney Docket Number	NIELSEN 3A		

OTHER PRIOR ART- NON PATENT LITERATURE DOCUMENTS								
Examin Initials*		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
Yh	$\langle \rangle$	AM	RAJORA, et al., α-MSH Modulates Experimental Inflammatory Bowel Disease, Peptides, 1997, 381-385, 18(3)					
		AN	STAR, et al., Evidence of Autocrine Modulation of Macrophage Nitric Oxide Synthase by α-melanocyte-stimulating Hormone, Proc. Natl. Acad. Sci. USA, 1995, 8016-8020, 92					
		AO	SADAMOTO, et al., Erythropoletin Prevents Place Navigation Disability and Cortical Infarction in Rats with Permanent Occlusion of the Middle Cerebral Artery, Biochemical and Biophysical Research Communications, 1998, 26-32, 253					
		AP	SAKANAKA, et al., In vivo Evidence that Erythropoietin Protects Neurons from Ischemic Damage, Proc. Natl. Acad. Sci. USA, 1998, 4635-4640, 95					
		AQ	SQUANDRITO, et al., Recombinant Human Erythropoletin Inhibits iNOS Activity and Reverts Vascular Dysfunction in Splanchnic Artery Occlusion Shock, British Journal of Pharmacology, 1999, 482-488, 127					
		AR	SQUADRITO, et al., Adrenocorticotropin Reverses Vascular Dysfunction and Protects Against Splanchnic Artery Occlusion Shock, British Journal of Pharmacology, 1999, 816-822, 128					
Y,	<i>(</i> /)	AS	CHIAO, et al., α-Melanocyte-stimulating Hormone Protects Against Renal Injury after Ischemia in Mice and Rats, J. Clin. Invest., 1997, 1165-1172, 99(6)					
			·					
			./					
	Examiner Signature Date Considered Do 05							

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.